Filing Details
- Accession Number:
- 0001055947-12-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-11-02 18:36:53
- Reporting Period:
- 2012-10-26
- Filing Date:
- 2012-11-02
- Accepted Time:
- 2012-11-02 18:36:53
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 918923 | P L Fund Value Biotechnology | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
| 1055947 | P/Il L Partners Bvf | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
| 1056807 | Bvf Inc/Il | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
| 1233840 | N Mark Lampert | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-10-26 | 12,515 | $15.26 | 737,551 | No | 4 | P | Indirect | See Explanation of Responses |
| Common Stock | Acquisiton | 2012-10-31 | 4,076 | $14.99 | 741,627 | No | 4 | P | Indirect | See Explanation of Responses |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Explanation of Responses |
| No | 4 | P | Indirect | See Explanation of Responses |
Footnotes
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Partners L.P. ("Partners"), BVF Inc., and Mark Lampert (collectively the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a section 13G group that collectively owns more than 10% of the Issuer's oustanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
- Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
- Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request
Billionaire Hedge Funds
